media advisory

Wednesday, August 10, 2022

Protein measured on the day of injury helps determine prognosis.


A study funded by the National Institutes of Health found that biomarkers present in the blood on the day of traumatic brain injury (TBI) accurately predicted a patient’s risk of death or severe disability six months later. It turns out that you can. According to the results presented today, measuring these biomarkers may provide a more accurate assessment of patient prognosis after TBI. lancet neurology.

Researchers transforming traumatic brain injury research and clinical knowledge (TruckTBI) examined levels of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), proteins found in glial cells and neurons, respectively, in approximately 1,700 TBI patients. . TRACK-TBI is an observational study aimed at improving the understanding and diagnosis of TBI to develop successful treatments.

The research team measured biomarkers in blood samples taken from TBI patients on the day of trauma and assessed recovery six months later. Participants were recruited from 18 high-level trauma centers across the United States. . More than half (57%) suffered TBI as a result of a road accident.

This study showed that GFAP and UCH-L1 levels on the day of injury were strong predictors of death and unfavorable outcomes such as vegetative state and severe disability requiring daily assistance. . Those with the fifth highest biomarker level had the highest risk of death 6 months after TBI, with most occurring within the first month.

GFAP and UCH-1 are currently used to help detect TBI. Elevated daily blood levels of TBI are associated with neuroimaging-visible brain damage. In 2018, the U.S. Food and Drug Administration approved the use of these biomarkers to help clinicians decide whether to order a head CT scan to examine the brain after mild traumatic brain injury. rice field.

New research suggests that GFAP and UCH-L1 may also help predict recovery, especially in patients with moderate to severe TBI. Biomarkers have improved the accuracy of current prognostic models.

The researchers found that the predictive value of biomarkers was strongest in patients with moderate to severe traumatic brain injury. However, biomarkers did not accurately predict a person who would experience incomplete recovery (moderately disabled but able to live independently) six months later.

Although additional studies are needed to replicate the results, the results suggest that blood-based biomarkers may help clinicians and researchers better predict patient outcome after traumatic brain injury. indicates that there is


NINDS program director, Dr. Nsini Umoh, is available to discuss research findings, TRACK-TBI, and current traumatic brain injury research. Contact us to arrange an interview [email protected].


Corey FK and others Prognostic value of day-of-injury plasma GFAP and UCH-L1 levels for predicting functional recovery in the TRACK-TBI cohort: an observational cohort study. September 2022. Lancet Neurology; 21:803-813.

TRACK-TBI is sponsored by the National Institute of Neurological Diseases and Stroke (Grant # U01 NS1365885), US Department of Defense, Abbott Research Institute, One Mind.

NINDS is the nation’s leading funder of research on the brain and nervous system.the mission of NINDS To explore the basic knowledge of the brain and nervous system and use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH):NIH, the United States medical research agency, has 27 laboratories and centers and is part of the US Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research investigating the causes, treatments, and cures for both common and rare diseases. . For more information about NIH and its programs, visit

NIH…turning discovery into health®